A Safety and Preliminary Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Evaluate the safety of the DaRT treatment
研究概览
简要总结
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
详细描述
This will be a prospective, open label, single arm, controlled study, assessing the safety and efficacy of diffusing alpha emitters radiation therapy (DaRT) delivered through radioactive seeds inserted into the tumor.
This approach combines the advantages of local intratumoral irradiation of the tumor, as used in conventional brachytherapy, with the power of the alpha radiation emitting atoms, that will be introduced in quantities considerably lower than radiation therapy already used in patients.
Superficial lesions with histopathological confirmation of malignancy will be treated using DaRT seeds.
Reduction in tumor volume and evaluation the percent of necrotic tissue in the tumor 30-45 days after DaRT seeds insertion (15-30 days after seed removal) will be assessed. Safety will be assessed by the cumulative incidence, worst severity and frequency of adverse events (AEs) observed including the follow-up period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with histopathological confirmation of cutaneous and/or mucosal and/or superficial soft tissue malignant neoplasia.
- •Subjects with a tumor size ≤ 5 centimeters in the longest diameter.
- •Subjects' age is over 18 years old.
- •Subjects' ECOG Performance Status Scale is <
- •Subjects' life expectancy is more than 6 months.
- •Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test.
- •Subjects are able and willing to sign an informed consent form.
排除标准
- •Subject has a tumor with a maximal diameter > 5 centimeters.
- •Subjects' ECOG Performance Status Scale is >
- •Subject has a tumor of Keratoacanthoma histology.
- •Patients with moribund diseases, e.g., autoimmune diseases, vasculitis, etc.
- •Patients under systemic immunosuppressive and/or corticosteroid treatment. Patients taking corticosteroid inhalers are eligible.
结局指标
主要结局
Evaluate the safety of the DaRT treatment
时间窗: 5-7 weeks after DaRT seed insertion.
The study primary objective is to evaluate the safety of the DaRT treatment in terms of incidence of device related Serious Adverse Events (SAE).
次要结局
- Evaluation the effectiveness of the treatment.(Tumor volume will be measured during screening, 5 and 30-45 days post DaRT after treatment using CT.)